hip and knee joint disease
Conditions
Interventions
The group A:Olanzapine 2.5mg qn was taken orally from the day of admission for a total of 5 days during the perioperative period (primary TKA/THA)
The group B:Alprazolam 4mg qn was taken orally from the day of admission for a total of 5 days during the perioperative period (primary TKA/THA)
The group C:There was no intervention on emotion and sleep during perioperative period
The group D:Olanzapine 2.5mg qn was taken orally from the day of admission for a total of 5 days during the perioperative period (revision TKA/THA)
The group E:Alprazolam 4mg qn was taken orally from the day of admission for a total of 5 days during the perioperative period (revision TKA/THA)
Sponsors
Department of Orthopaedic surgery, West China Hospital, Sichuan University.
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Patients between 18 and 80 years were scheduled to undergo primary and revision THA/TKA for end-stage hip/knee disease and had abnormal STAI scores before surgery or significant anxiety symptoms.
Exclusion criteria
Exclusion criteria: (i) the patient cannot swallow tablets; (ii) the patient is taking antipsychotic drugs, or has been diagnosed with psychiatric disorders; (iii) the presence of severe cardiovascular disease or past history: preoperative electrocardiogram-corrected QT interval greater than 450 ms, or a history of tip-twisting; previous, myocardial infarction or unstable angina pectoris, cardiac arrhythmia, congestive heart failure, recent postural hypotension or vasovagal syncope, or perioperative Patients with hypotension (systolic blood pressure less than 90 mmHg); ? Severe hepatic or renal impairment: serum creatinine level of 2.0 milligrams per deciliter (177 µmmol/L) or higher; and aspartate or alanine aminotransferase levels greater than three times the upper limit of the normal range; ? Patients with contraindications to olanzapine, including known drug allergies, Parkinson's disease, or dementia with Lewy bodies; ? Uncontrolled diabetes; ? Known history of central nervous system disease (e.g., brain metastases or epilepsy); ? Concomitant use of quinolone antibiotics or ketoconazole or itraconazole; ? Opioid or alcohol dependence; ? Myasthenia gravis; ? Acute or easy-to-occur closed-angle glaucomatous eye episodes; ? Severe chronic obstructive pulmonary disease; ? Unable to comprehend the content of the STAI questionnaire or do not understand the survey;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| State-Trait Anxiety Inventory-State score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Visual analogue scale-Pain score;Visual analogue scale-Sleep disorder score;Visual analogue scale-Nausea;Incidence of postoperative vomiting;Harris Hip Score and Hospital for Special Surgery Knee Score;range of motion of hip and knee;postoperative consumption of opioids;Length of stay;Incidence of postoperative complications ;adverse reactions related to drugs;Patient satisfaction; | — |
Countries
China
Contacts
Public ContactZongke Zhou
Department of Orthopaedic surgery, West China Hospital, Sichuan University.
Outcome results
None listed